Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated October 6, 2023, reports a stock-exchange announcement regarding the company's intention to sell a portion of its stake in Haleon plc. The filing does not contain financial results for a specific reporting period but rather details a corporate action.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The primary financial data points relate to equity holdings:
- Shares to be sold: 270 million ordinary shares in Haleon.
- Percentage of Haleon capital: Approximately 2.9% of Haleon's issued share capital.
- Pre-transaction GSK stake: Approximately 10.3% (following a prior sale of 240 million shares in May 2023).
- Post-transaction GSK stake: Expected to reduce to approximately 7.4% (calculated as 10.3% minus 2.9%).
- Offer Price: To be determined via an accelerated bookbuild process; no specific price is provided in this text.
Material Changes
The material change announced is the reduction of GSK's equity interest in Haleon. Following the demerger in July 2022, GSK retained a 12.94% stake. After a sale in May 2023, the stake was reduced to 10.3%. This new transaction will further reduce GSK's holding by approximately 2.9%.
Guidance, Outlook, and Risks
Transaction Structure: The disposal will be conducted through a placing of shares to institutional investors. BofA Securities and Citigroup Global Markets Limited are appointed as Joint Global Coordinators.
Lock-up Period: GSK and Pfizer (which holds a 32% stake in Haleon) have undertaken not to dispose of any Haleon shares for 60 days following the settlement of this offering, subject to customary exceptions.
Risks and Contingencies:
- The announcement does not represent a definitive agreement; there is no certainty the offering will proceed.
- GSK reserves the right to vary terms or not proceed with the offering.
- Forward-looking statements are subject to risks described in GSK's 2022 Form 20-F and Q2 2023 results, including the impact of the COVID-19 pandemic.
- The securities may not be offered or sold in the United States absent registration or an exemption.
Investor Verification Checklist
- Verify the final offer price and total proceeds once the accelerated bookbuild process is completed.
- Confirm the exact settlement date to determine the start of the 60-day lock-up period for GSK and Pfizer.
- Review the definitive agreement (if executed) to confirm any changes to the number of shares or terms.
- Check subsequent filings for the updated percentage of Haleon shares retained by GSK post-settlement.